US 10143748
B-cell reduction using CD37-specific and CD20-specific binding molecules
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10143748 (B-cell reduction using CD37-specific and CD20-specific binding molecules) held by Aptevo Research and Development LLC expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aptevo Research and Development LLC
- Grant date
- Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/3955